STOCK TITAN
  1. Home
  2. News
  3. ADILW

Adial Pharmaceuticals Inc - ADILW STOCK NEWS

Welcome to our dedicated news page for Adial Pharmaceuticals (Ticker: ADILW), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adial Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adial Pharmaceuticals's position in the market.

News
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) reported receiving Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award, closed a $4 million private placement, and extended its cash runway into Q4 2024. The company is advancing discussions with potential strategic partners and has made steady progress throughout the third quarter of 2023. Adial is pursuing a highly focused regulatory strategy and is finalizing its clinical development plan for AD04, aiming for approval in the U.S. and EU. The company is also under confidentiality agreements and in discussions with companies interested in supporting the development and commercial launch of AD04. Adial has improved its balance sheet as a result of the recent private placement and received the 2023 Best Practices Technology Innovation Leadership Award in the North American precision medicine for addiction disorders industry by Frost & Sullivan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
earnings
-
News
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference
Rhea-AI Summary
Adial Pharmaceuticals, Inc. will be presenting at The Annual International Society of Addiction Medicine Conference. The presentation will highlight the effects of AD04, the Company's therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The phase 3 clinical trial results support the use of AD04 as a precision medicine to treat AUD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
News
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar
Rhea-AI Summary
Adial Pharmaceuticals recently hosted a webinar with addiction experts to discuss the need for non-abstinence-based therapies for alcohol use disorder (AUD). Current medications are not widely prescribed or utilized, and adherence is a concern. The experts believe that non-abstinence-based treatments can reduce barriers to treatment and improve patient engagement. They emphasize that reductions in excessive drinking, even without complete abstinence, can have a major public health impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
News
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
Adial Pharmaceuticals has closed its private placement offering, raising approximately $4 million in gross proceeds. The company plans to use the net proceeds for general corporate purposes and to support regulatory and clinical activities related to its lead drug product for the treatment of Alcohol Use Disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
News
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
Adial Pharmaceuticals announces private placement of common stock and warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.11%
Tags
none
-
News
Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
Rhea-AI Summary
Adial Pharmaceuticals announces the award of a key patent for the use of its genetic diagnostic tool in combination with its drug AD04 for the treatment of alcohol use disorder and opioid use disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
News
Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award
Rhea-AI Summary
Adial Pharmaceuticals receives Best Practices Technology Innovation Leadership Award in precision medicine for addiction disorders industry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
-
News
Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder
Rhea-AI Summary
Pre-registration for Adial Pharmaceuticals' LinkedIn Live event discussing non-abstinence-based therapies in Alcohol Use Disorder (AUD) begins on September 28th. The event will feature industry experts Joseph Volpicelli and Jonathan Hunt-Glassman, and will be moderated by Kemp Dolliver. The webinar aims to address the current treatment landscape and the need for non-abstinence-based therapeutics. The event will take place on October 4th at 2:15 p.m. ET, with a replay available afterwards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14%
Tags
conferences
-
News
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Adial Pharmaceuticals CEO to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
News
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism
Rhea-AI Summary
Adial Pharmaceuticals to present at ESBRA conference on new approaches in the treatment of Alcohol Use Disorder (AUD) through precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
Stock ADILW logo
Adial Pharmaceuticals Inc

Nasdaq:ADILW

ADILW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ADILW Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About ADILW

adial pharmaceuticals is dedicated to personalized treatment for drug abuse and addiction. while our pipeline includes drug candidates for the treatment of opiate and amphetamine use, our two lead drug candidates are for the treatment of alcohol abuse. adial leverages its extensive knowledge of pharmacology and pharmacogenomics to change the paradigm of drug abuse treatment.